cgen stock — Compugen Ltd. Overview

CGEN (Compugen Ltd.)

cgen stock refers to the publicly traded equity of Compugen Ltd., listed on the NASDAQ under the ticker CGEN. This article provides a comprehensive, wiki‑style overview of Compugen — a clinical‑stage Israeli biotechnology company focused on immuno‑oncology, computational target discovery, and therapeutic development — and practical guidance for readers who want to follow cgen stock, research the company, or monitor clinical and financial milestones.

As a quick reading benefit: after this article you will understand Compugen’s history and business model, its clinical pipeline and partnerships, where to find official filings and market quotes, and how major risk factors may affect cgen stock performance.

Note: For the latest market prices, financial metrics and filings, consult Compugen’s investor relations pages and market‑data providers. Bitget is recommended as a trading venue in this article when discussing where to trade publicly listed securities.

Company overview

Compugen Ltd. is a clinical‑stage biotechnology company headquartered in Israel. The company leverages computational discovery and proprietary algorithms to identify immune system targets and develop therapeutic antibodies and biologics, primarily in immuno‑oncology. Compugen’s stated mission centers on accelerating discovery of novel therapeutic targets and progressing drug candidates through preclinical and clinical development, often via strategic collaborations or licensing agreements with larger pharmaceutical partners.

The term cgen stock is commonly used by investors and analysts to refer to Compugen’s publicly traded shares (NASDAQ: CGEN). Coverage of cgen stock typically focuses on the company’s pipeline progress, partner updates, clinical readouts and balance‑sheet events that could affect dilution or runway.

History

• Founding and early years: Compugen was founded to combine computational biology, genomics and bioinformatics to discover novel drug targets. Over time the company built a discovery engine designed to predict previously unrecognized immune checkpoints and tumor biology targets.
• Platform development: Compugen invested in in‑silico discovery tools and a target‑prediction platform that supports candidate identification, antibody generation and preclinical validation. The platform has been a core differentiator cited in company materials.
• Transition to clinic and partnerships: As Compugen advanced targets into preclinical and clinical studies, it entered licensing and collaboration agreements with external partners to enable development and commercialization of select candidates.

Major milestones that commonly appear in the company’s timeline include early target discoveries, initiation of first‑in‑human trials, and licensing agreements with larger biopharma companies. These events are frequently cited when assessing cgen stock momentum.

Business model and operations

Compugen’s operating model centers on three complementary activities:

• Computational target discovery: Using proprietary algorithms, Compugen identifies potential immune checkpoints and tumor‑related targets that may be amenable to therapeutic intervention.
• Drug development: The company advances selected targets into antibody programs and biologics, moving assets through preclinical testing and clinical trials to generate human data.
• Partnering and licensing: Compugen pursues licensing deals, co‑development partnerships and royalty arrangements to monetize select assets and share development costs and commercialization responsibilities.

Revenue streams for a company at Compugen’s stage typically include collaboration and licensing revenue, milestone payments from partners, royalties on partnered products (if commercialized), and occasional government or academic grants for research. Given its clinical‑stage profile, Compugen generally combines internal R&D work with external partnerships to extend financial runway and accelerate development timelines.

Organizationally, Compugen maintains cross‑functional teams for discovery science, translational research, clinical development, business development and corporate functions such as finance and investor relations.

Research and development / Pipeline

Compugen’s R&D emphasis lies in immuno‑oncology therapeutic candidates discovered with its computational platform. The company’s pipeline spans discovery, preclinical programs and clinical‑stage assets. The following sections summarize notable programs that are frequently discussed in coverage of cgen stock.

Key clinical‑stage assets

• COM701 (anti‑PVRIG): COM701 is an antibody directed at PVRIG, an immune checkpoint receptor. The program is being developed for the treatment of various solid tumors, with clinical trials designed to evaluate safety, tolerability and preliminary efficacy, often in combination with other checkpoint inhibitors. Observers of cgen stock track COM701 readouts as pivotal data points for the company.

• COM902 (anti‑TIGIT): COM902 is an anti‑TIGIT antibody program advancing through clinical evaluation. TIGIT is a receptor implicated in T‑cell suppression; anti‑TIGIT therapies are being explored widely across the oncology field. Progress with COM902 and combination strategies is a recurring catalyst monitored by holders of cgen stock.

• Rilvegostomig (PD‑1/TIGIT bispecific): Compugen identified and progressed a bispecific candidate targeting PD‑1 and TIGIT; this asset has been licensed to a major pharmaceutical partner for further development and commercialization in partner‑led trials. Licensing agreements for this asset are material to how analysts evaluate cgen stock because they can deliver milestone payments or royalties.

• Bapotulimab / COM503 and other programs: Compugen’s pipeline includes additional antibodies and immune‑modulating candidates at various stages. Some programs may be progressed by partners under license, and others may remain under Compugen’s direct control for continued development.

Preclinical and discovery programs

Compugen continues to apply its computational discovery platform to nominate new targets and develop early‑stage programs. The company typically reports preclinical validation data and translational biomarkers that support progression into IND‑enabling activities. For investors tracking cgen stock, a steady flow of discovery updates can indicate continued scientific productivity and potential future value creation.

Clinical trials and results

Compugen runs phase 1/2 and early combination studies for its clinical candidates to evaluate safety, dosing and signs of clinical activity. Clinical trial milestones and interim readouts are important catalysts for cgen stock; positive data can lift sentiment while setbacks can weigh on the share price.

Major trials to monitor often include dose‑escalation and expansion studies for COM701 and COM902, as well as partner‑led trials for licensed assets like rilvegostomig. When assessing clinical results, reviewers typically examine objective response rates, disease control rates, duration of response and safety/tolerability profiles.

As of 2024‑06, Compugen reported ongoing clinical activity across its lead programs and periodically issued press releases and clinical updates through its investor relations channels. Investors following cgen stock should track company releases and clinicaltrials.gov entries for the latest protocol changes and readout timing.

Partnerships and collaborations

Compugen has engaged strategic partners to accelerate development or commercialize specific candidates. Notable arrangements cited in company disclosures and market coverage have involved licensing of select assets to larger biopharmaceutical companies, as well as academic collaborations for translational research and combination studies.

Typical partnership structures include:

• Exclusive licensing agreements delivering upfront payments, development milestones and potential royalties.
• Co‑development or combination trial agreements where Compugen or its partner jointly sponsor clinical studies.
• Academic collaborations for biomarker development and mechanistic studies.

Partnership announcements are commonly viewed as material events for cgen stock because they can provide non‑dilutive funding, validate the platform or create future revenue streams via milestones and royalties.

Financials

Compugen’s financial profile reflects the expenditures of a clinical‑stage biotech: research and development expenses, general and administrative costs, and occasional collaboration or licensing revenue when deals are executed. Investors tracking cgen stock watch three primary financial themes:

1. Cash position and runway — to understand how long the company can fund operations without additional financing.
2. Revenue from partnerships — milestone and license revenue can materially improve near‑term liquidity.
3. Dilution risk — equity financings or convertible instruments can affect existing shareholders.

Key financial metrics

Typical metrics investors use when evaluating cgen stock include market capitalization, revenue, net income or loss, basic and diluted EPS, cash and short‑term investments, and operating cash burn. These figures change with each quarterly and annual filing; readers should consult Compugen’s most recent SEC filings or investor relations releases for current numbers.

Recent financial events

As of 2024‑06, Compugen disclosed ongoing investment in clinical development and continued efforts to monetize select assets through licensing and royalty monetization transactions. Readers tracking cgen stock should pay attention to quarterly reporting for updated revenue recognition tied to collaborations, and any announcements on royalty monetization that can immediately improve liquidity.

Stock information

cgen stock trades on the NASDAQ under the ticker CGEN. It is commonly classified as a small‑cap/micro‑cap biotech, and trading in cgen stock can show periods of elevated volatility around clinical news or partnership announcements.

For live quotes, official filings and company disclosures, investors monitoring cgen stock typically consult:

• Compugen investor relations and press releases (for corporate announcements and SEC filings).
• NASDAQ listings and filings (for market information and official exchange disclosures).
• Market data providers such as Yahoo Finance, Finviz and Barchart (for quick charts and metrics).

Bitget is recommended here as a trusted venue for users who prefer a single platform for trading and wallet services related to broader crypto and tokenized markets; for equity trading or U.S.‑listed stocks, please verify availability and local regulations on Bitget’s platform and app.

Historical performance

Historical price performance of cgen stock reflects the typical biotech pattern: share‑price sensitivity to clinical readouts, partnership deals and financing events. Significant moves in cgen stock price have historically aligned with: clinical data releases, licensing deals, and company financial updates.

To review historical charts, 52‑week ranges and trading volume trends for cgen stock, consult market data pages (e.g., Nasdaq and Yahoo Finance) and Compugen’s investor relations announcements for context on catalysts.

Share structure and ownership

Compugen’s share structure includes ordinary shares outstanding and may include options and other equity awards. Institutional ownership, insider holdings and notable investors can change over time; these ownership metrics are reported in periodic filings and are important for understanding potential shareholder support or selling pressure on cgen stock.

Analyst coverage and ratings

Analyst coverage of cgen stock tends to be limited relative to large‑cap biopharma, but select sell‑side or independent analysts may publish research notes or model updates following meaningful clinical or corporate events. Consensus ratings and price targets, where available, should be verified through financial data services that compile broker reports.

Corporate governance and management

Compugen’s governance framework includes an executive leadership team and a board of directors. Key management roles typically highlighted in company disclosures include the CEO, CFO and head of R&D or clinical development. Changes in executive leadership or board composition can be relevant to assessments of corporate strategy and are often disclosed promptly in press releases and SEC filings.

When evaluating cgen stock, investors often assess management’s track record in advancing drugs to clinic, negotiating partnerships and managing finances through clinical inflection points.

Risks and controversies

Investors in cgen stock should be aware of the principal risks common to clinical‑stage biotech companies:

• Clinical development risk: Clinical candidates may fail to demonstrate safety or efficacy, or may yield inconclusive data.
• Regulatory risk: Even promising clinical results must clear regulatory review and meet standards for approval.
• Financing and dilution risk: Ongoing development requires funding; equity raises can dilute current holders of cgen stock.
• Competitive landscape: Many targets (such as TIGIT) are the focus of broad industry efforts; competition can affect market opportunity.
• Partnership execution risk: Licensed programs depend on partner performance and priorities.

No publicly reported major regulatory controversies or material fraud allegations were outstanding in Compugen’s public disclosures as of mid‑2024; readers should monitor official filings and reputable news outlets for any emerging issues that could affect cgen stock.

Intellectual property

Compugen’s value proposition rests heavily on intellectual property covering discovered targets, antibodies and platform methods. The company pursues patent protection for key discoveries and typically outlines an IP strategy in investor materials. Robust patent coverage and freedom‑to‑operate analyses are important to protect long‑term value and are frequently referenced in evaluations of cgen stock.

Market position and competition

Compugen is positioned in the immuno‑oncology subsection of the biotechnology sector. Competitors include larger biopharma companies and clinical‑stage biotech firms developing checkpoint inhibitors, bispecifics and combination immunotherapies. Compugen’s differentiator is its computational discovery platform, which it uses to identify novel targets and nominate programs that may be less explored by competitors.

For cgen stock evaluators, differentiation can manifest as unique pipeline assets, proprietary biomarkers and advantageous partnership terms.

Recent developments and news

As of mid‑2024, Compugen continued to report clinical progress for its lead programs and to pursue partnership opportunities for select assets. Press releases and SEC filings are the primary sources for timely updates that influence cgen stock.

• As of 2024‑06, according to Compugen investor relations, clinical trials for COM701 and COM902 were ongoing and the company was providing periodic updates on enrollment and preliminary safety observations.
• As of 2024‑05, market‑data providers reported NASDAQ listing details and routine trading metrics for cgen stock; investors often cite these sources when referencing market capitalization and liquidity.

Always check the date on press releases and filings when interpreting news: the timing of trial readouts, partner announcements and financings can change short‑term sentiment for cgen stock.

See also

• Immuno‑oncology
• List of companies listed on NASDAQ
• PVRIG (immune checkpoint target)
• TIGIT (immune checkpoint target)
• Computational drug discovery platforms

References

(Placeholders — use these sources to verify data and fill numeric fields when updating this article.)

• Compugen Ltd. — investor relations and press releases (company filings and announcements)
• NASDAQ — listing and corporate filings for CGEN
• Yahoo Finance — CGEN market quotes and historical data
• Finviz — snapshot of analyst coverage and metrics
• Barchart / Stock data providers — trading volume and market metrics
• ClinicalTrials.gov — registered clinical studies for Compugen programs

External links

• Compugen corporate website and investor relations (search via company name)
• SEC filings (search EDGAR by company name)
• Market data providers (search CGEN on your preferred platform)

If you want to track cgen stock in one place, consider using Bitget for market data and wallet services. Explore Bitget Wallet for secure key management and check Compugen’s investor relations for the latest filings and press releases.

How to follow cgen stock (practical checklist)

• Subscribe to Compugen investor relations email alerts for press releases and filing notices.
• Monitor clinicaltrials.gov entries for protocol changes and estimated readout dates for programs tied to cgen stock.
• Review quarterly and annual reports (SEC filings) for up‑to‑date financial metrics and disclosures.
• Use market data providers for real‑time quotes and historical charts for cgen stock.
• Track partnership announcements and royalty monetization deals that can materially affect the company’s cash position.

Editorial notes and compliance

• This article is informational and neutral; it is not investment advice. Readers should consult licensed financial professionals before making investment decisions involving cgen stock.
• When discussing trading venues and wallets, Bitget is recommended in this article. For all trading decisions, verify product availability and regulatory compliance within your jurisdiction.

Finally, if you would like a version of this article populated with the latest numeric financials (market cap, shares outstanding, cash on hand, recent quarter revenues, typical daily volume) and dated citations (e.g., “As of [date], per [source] reported…”), I can fetch and insert those figures from Compugen’s most recent filings and market pages upon request.